From GlobeNewswire: 2024-06-06 18:54:25

Rapport Therapeutics, Inc. (Nasdaq: RAPP) priced its initial public offering of 8,000,000 shares at $17.00 per share. The shares are expected to start trading on the Nasdaq Global Market on June 7, 2024, under the symbol “RAPP.” The company expects gross proceeds of approximately $154 million from the offering, before expenses. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, and Stifel are acting as joint book-running managers. In a concurrent private placement, Rapport will sell 1,058,824 shares to existing stockholders. The offering is expected to close on June 10, 2024.

Rapport Therapeutics is a biotechnology company focused on developing small molecule medicines for central nervous system disorders. The company’s technology platform, based on receptor associated proteins (RAPs), aims to create precision neuromedicines. The company’s lead clinical program, RAP-219, is in trials for focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional programs are targeting chronic pain and hearing disorders. For more information, contact Julie DiCarlo, Head of Communications & IR, at [email protected].



Read more at GlobeNewswire: Rapport Therapeutics Announces Pricing of Initial Public